Why viruses are so hard
A bacterium is a self-contained cell with its own machinery to sabotage. A virus is barely a creature at all — a scrap of genes in a coat that hijacks your own cells to copy itself. That makes selective toxicity brutally hard: many of the steps a virus needs are run by your machinery, and you cannot poison those without poisoning yourself.
The winning strategy is to find the virus-specific steps — the few enzymes a virus brings that have no human counterpart. Those become the drug targets, and each defines a mechanism of action that can hurt the virus while leaving the cell intact.
The attackable steps
Trace a viral life cycle and you find a handful of choke points. The two most exploited are the enzymes that copy the genome and the enzymes that cut viral proteins into shape:
Viral life cycle -> drug targets
================================
entry / fusion block the virus latching onto the cell
uncoating stop the genome from being released
genome copying POLYMERASE INHIBITORS <- biggest class
(nucleoside analogs jam the growing chain)
protein maturation PROTEASE INHIBITORS
(block the viral scissors that finalize proteins)
assembly/release block budding (e.g. neuraminidase in flu)
Most antiviral drugs cluster at copying and maturation,
because those enzymes are uniquely viral.Polymerase inhibitors are the workhorses. Many are nucleoside analogs — fake versions of the A, C, G, T building blocks. The viral polymerase grabs the imposter and stitches it into the growing strand, but the fake lacks the hook the next nucleotide needs, so copying stalls. Because viral polymerases are sloppier and faster than ours, they take the bait more readily, which buys back some selectivity.
Designed by structure, delivered by prodrug
The triumph of viral protease inhibitors shows medicinal chemistry at its sharpest. A protease is molecular scissors the virus needs to finalize its proteins. Because we could crystallize the HIV and hepatitis C proteases, chemists used structure-based drug design to sculpt molecules that wedge perfectly into the active site — a mechanism that cripples the virus and turned HIV from a death sentence into a managed condition.
Step back and the whole track rhymes. β-lactams exploit a wall we lack; antivirals exploit enzymes we lack. MIC and resistance for bacteria have exact echoes in viral load and viral resistance. Whatever the pathogen, the craft is the same: find the difference, design the molecule, and stay humble about the arms race ahead.